Clin2
NCT07707778Possibly a fitEnrolling by invitation

Tirzepatide for Weight and Aging in People with HIV

Human Immunodeficiency Virus (HIV)Metabolic Dysfunction Associated Steatotic Liver DiseaseDyslipidaemiaDiabetes MellitusObesity & OverweightMetabolic Syndrome

Treatments studied

Part of Hormones & metabolism, Immune system & allergy, Infections clinical trials.

This trial tests whether a weight-loss medicine called tirzepatide can slow biological aging and improve metabolism in people with HIV who are already on effective treatment. It may help you reduce weight and possibly reverse some signs of aging.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 4
Enrollment
60 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are an adult living with HIV.
  • Your HIV is well-controlled (viral load under 200 copies/mL in the last 6 months).
  • Your BMI (body mass index) is over 30, which is considered obesity.
  • You have not taken GLP-1 or similar weight-loss or diabetes medicines (like Ozempic, Wegovy, or Mounjaro) in the last 90 days.
  • You do not have any active AIDS-related illnesses, active cancer, or a history of severe liver failure.
  • You have never had acute pancreatitis or a family history of medullary thyroid cancer, and you are not pregnant.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07738276Not yet recruiting· Phase 3
Tirzepatide for heart failure patients with obesity

This trial tests a medicine called tirzepatide, given as an injection, to see if it can improve daily function and symptoms in people with a weak heart (heart failure with reduced ejection fraction) who also have obesity. Tirzepatide works on two natural hormones to help with weight and may also improve heart health.

NCT06811324Recruiting· Phase 2
Tirzepatide for muscle and vessel health in older adults

This study tests if the drug tirzepatide can improve muscle and blood vessel health in older adults with obesity. You may be eligible if you are 50 or older, have a BMI between 30 and 40, and do not have diabetes.

San Antonio, Texas
NCT05912621Recruiting· Phase 2
Tirzepatide for fat-related body dysfunction in overweight adults

This Phase 2 study tests whether tirzepatide can improve how your body handles fat (especially in people with overweight or obesity) and reduce fat-related “lipotoxicity.” It may help with body fat function and related health markers, but you must meet specific health and medication rules.

Palo Alto, California
NCT07099742Not yet recruiting
Tirzepatide for weight loss in adults with obesity

This study tests if tirzepatide helps people with obesity lose weight, whether or not they have type 2 diabetes. It aims to see how safe and effective the drug is.

Comilla
NCT07247084Recruiting· Phase 4
Tirzepatide for weight loss in adults with obesity

This trial tests if tirzepatide is more effective than standard obesity treatments for adults who have a BMI between 30 and 35 and one weight-related health condition, but do not have diabetes. The goal is to help you lose weight.

Altrincham
NCT07220473Recruiting· Phase 2
Tirzepatide to slow biological aging

This study tests whether the medication tirzepatide (a drug used for diabetes and weight loss) can slow the biological aging process in adults aged 55 to 70 who have excess weight. You would take the medication as a weekly injection for a set period, and researchers will monitor changes in your body's health markers.

Galveston, Texas

Hear when a new Metabolic Dysfunction-Associated Steatotic Liver Disease trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.